Vaccine

RSV (Respiratory Syncytial Virus) Vaccine

This study is testing a new vaccine to protect women from getting sick from RSV.

Ages:

18 - 49

Reimbursement:

up to $300

Trial Length:

Up to 6 months

Qualifications:

  • Ages 18-49 non-pregnant women

Additional Information

This study is testing a new vaccine to protect women from getting sick from RSV (a germ that can cause cold like symptoms). Later, the ultimate plan for this vaccine will be to provide it to pregnant women, and hope see if boosted antibodies will be able to reach the baby through the placenta.

This study is not being used in pregnant women – just women of childbearing age.